Merck & Company Inc (MRK)vsVistaGen Therapeutics Inc (VTGN)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
VTGN
VistaGen Therapeutics Inc
$0.24
-0.84%
HEALTHCARE · Cap: $11.02M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2661595% more annual revenue ($66.57B vs $2.50M). MRK leads profitability with a 4.8% profit margin vs 0.0%. VTGN earns a higher WallStSmart Score of 38/100 (F).
MRK
Hold36
out of 100
Grade: F
VTGN
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+88.9%
Fair Value
$4.91
Current Price
$0.24
$4.67 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Revenue surging 505.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : VTGN
The strongest argument for VTGN centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 505.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : VTGN
The primary concerns for VTGN are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while VTGN is a hypergrowth play — different risk/reward profiles.
VTGN carries more volatility with a beta of 0.38 — expect wider price swings.
VTGN is growing revenue faster at 505.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
VTGN scores higher overall (38/100 vs 36/100) and 505.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →VistaGen Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential to treat anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?